Cart
sales@molnova.com
Cdk1,2 Inhibitor III
CAS No. 443798-55-8
Cdk1,2 Inhibitor III( —— )
Catalog No. M33311 CAS No. 443798-55-8
Cdk1/2 Inhibitor III is a selective inhibitor of Cdk1/2 with an IC50 value of 2.1 μM against CDK1/cyclin B.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 471 | In Stock |
|
| 10MG | 755 | In Stock |
|
| 25MG | 1121 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCdk1,2 Inhibitor III
-
NoteResearch use only, not for human use.
-
Brief DescriptionCdk1/2 Inhibitor III is a selective inhibitor of Cdk1/2 with an IC50 value of 2.1 μM against CDK1/cyclin B.
-
DescriptionCdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor, with an IC50 of 2.1 μM for CDK1/cyclin B.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number443798-55-8
-
Formula Weight425.44
-
Molecular FormulaC15H13F2N7O2S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(NC1=C(F)C=CC=C1F)(=S)N2C(NC3=CC=C(S(N)(=O)=O)C=C3)=NC(N)=N2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lin R, et al. Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11.?
molnova catalog
related products
-
CDK12-IN-3
CDK12-IN-3 is a selective and potent CDK12 inhibitor with anti-tumor activity, which can be used to study malignant tumors.
-
ICEC 0942 hydrochlor...
ICEC 0942 (CT7001) is a potent, selective, orally active CDK7 inhibitor with IC50 of 41 nM, displays 15-fold selectivity over CDK2 (IC50=578 nM).
-
(S)-Enitociclib
(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.
